Three new methods were added to the catalogue of SHI funds
Before a new diagnostic and treatment method can be offered and reimbursed in the outpatient sector, two important steps need to be
Tag: G-BA
ITC was accepted and improved additional benefit rating
In the recent early benefit assessment of nivolumab, the G-BA not only accepted the submitted ITC, but this also resulted in a
First COVID-19 drug has been assessed by G-BA
The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It
What is reference pricing?
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
The process of method assessments in Germany
The G-BA, physicians, hospitals, SHI funds or patient organizations can request the assessment of a new method. If the request was accepted,